@article{95805,
  keywords = {Public Health, Environmental and Occupational Health, Parasitology, Infectious Diseases, General Medicine, ivermectin (IVM)},
  author = {Kositz C and Bradley J and Hutchins H and Last AR and D'Alessandro U and Marks M},
  title = {Broadening the range of use cases for ivermectin – a review of the evidence},
  abstract = {<jats:title>Abstract</jats:title>
               <jats:p>Ivermectin is a broad-spectrum antiparasitic agent that interferes with glutamate-gated chloride channels found in invertebrates but not in vertebrate species. Mass drug administration (MDA) with ivermectin-based regimes has been a mainstay of elimination efforts targeting onchocerciasis and lymphatic filariasis for more than 3 decades. More recently, interest in the use of ivermectin to control other neglected tropical diseases (NTDs) such as soil-transmitted helminths and scabies has grown. Interest has been further stimulated by the fact that ivermectin displays endectocidal efficacy against various Anopheles species capable of transmitting malaria. Therefore there is growing interest in using ivermectin MDA as a tool that might aid in the control of both malaria and several NTDs. In this review we outline the evidence base to date on these emerging indications for ivermectin MDA with reference to clinical and public health data and discuss the rationale for evaluating the range of impacts of a malaria ivermectin MDA on other NTDs.</jats:p>},
  year = {2021},
  journal = {Transactions of The Royal Society of Tropical Medicine and Hygiene},
  publisher = {Oxford University Press (OUP)},
  issn = {0035-9203, 1878-3503},
  doi = {10.1093/trstmh/trab114},
  language = {eng},
}